#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14170	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2128	662.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1469	1469	C	872	C	811	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14170	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2128	662.3	0	HET	.	.	.	C451T	.	451	451	C	736	736	C	788	C,T	426,318	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26426	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3717	709.1	0	.	n	.	0	T695C	SNP	695	695	T	1045	1045	C	777	C,T,A	731,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26426	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3717	709.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2321	2321	C	884	C	817	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26426	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3717	709.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2395	2395	A	842	A,G	797,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26426	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3717	709.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2947	2947	C	793	C	742	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	26426	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3717	709.1	0	HET	.	.	.	A1638G	.	1638	1638	A	1988	1988	A	829	A,G	356,412	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	1808	folP	855	855	100.0	folP.l15.c30.ctg.1	1487	121.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1065	1067	AGC	185;186;186	A;G;C	170;173;173	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5048	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3241	154.9	1	SNP	p	S91F	1	.	.	271	273	TTC	498	500	TTC	179;179;180	T;T;C	167;166;168	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5048	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3241	154.9	1	SNP	p	D95G	1	.	.	283	285	GGC	510	512	GGC	179;177;177	G,A;G;C	171,1;171;168	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5048	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3241	154.9	1	SNP	p	G95N	0	.	.	283	285	GGC	510	512	GGC	179;177;177	G,A;G;C	171,1;171;168	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1524	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1223	123.6	1	SNP	p	G45D	0	.	.	133	135	GGC	416	418	GGC	194;193;192	G;G;C	180;179;176	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	822	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	901	90.7	0	.	n	.	0	A197.	DEL	197	197	A	501	501	A	204	A	190	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5508	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3044	180.3	1	SNP	p	D86N	0	.	.	256	258	GAC	689	691	GAC	236;236;237	G;A;C	221;218;221	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5508	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3044	180.3	1	SNP	p	R87W	0	.	.	259	261	CGT	692	694	CGT	239;237;237	C;G;T	224;222;217	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5508	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3044	180.3	1	SNP	p	S87R	1	.	.	259	261	CGT	692	694	CGT	239;237;237	C;G;T	224;222;217	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5508	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3044	180.3	1	SNP	p	R87I	0	.	.	259	261	CGT	692	694	CGT	239;237;237	C;G;T	224;222;217	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5508	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3044	180.3	1	SNP	p	S88P	0	.	.	262	264	TCC	695	697	TCC	235;237;239	T;C;C	217;220;222	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4018	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2551	156.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1459	1461	GGC	187;186;185	G;G;C	169;167;166	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1215	1217	GCC	206;203;203	G;C;C	192;191;193	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1218	1220	ATG	204;204;206	A;T;G	194;195;195	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1230	1232	ACC	194;194;194	A;C;C	185;183;182	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1230	1232	ACC	194;194;194	A;C;C	185;183;182	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1731	1733	ACC	214;216;218	A;C;C	190;196;197	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1785	1787	GCG	205;203;201	G,A;C;G	184,1;188;185	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1785	1787	GCG	205;203;201	G,A;C;G	184,1;188;185	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1908	1910	GGT	176;174;176	G;G;T	159;158;160	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1917	1919	AGC	172;167;165	A;G;C	156;154;151	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3998	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2275	174.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1935	1937	CCG	149;151;154	C,G;C;G	109,6;115;116	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5818	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	2988	193.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1587	1589	CCG	232;233;238	C;C;G,A	205;216;213,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2424	porA	1146	1146	99.91	porA.l6.c30.ctg.1	1965	123.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	651	651	C	179	C,G	159,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	480	482	GGA	210;212;212	G;G;A,G	196;198;193,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	0	.	p	.	0	F135L	NONSYN	403	405	TTT	741	743	CTT	207;209;209	C;T;T	195;194;198	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	765	767	GGA	206;206;205	G;G;A	196;193;189	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	0	.	p	.	0	D171G	NONSYN	511	513	GAT	849	851	GGT	194;194;196	G;G;T	180;180;175	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	0	.	p	.	0	G189S	NONSYN	565	567	GGC	903	905	AGC	200;200;197	A;G;C	185;182;181	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	969	969	T	194	T	185	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	1	SNP	p	G120K	0	.	.	358	360	GGT	696	698	GGT	199;196;199	G;G;T	190;183;180	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	1	SNP	p	A121N	0	.	.	361	363	GCC	699	701	GCC	200;198;198	G;C;C	188;191;189	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2594	porB1b	1035	1035	95.44	porB1b.l15.c4.ctg.1	1629	158.3	1	SNP	p	A121D	0	.	.	361	363	GCC	699	701	GCC	200;198;198	G;C;C	188;191;189	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11016	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4794	229.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1122	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1064	105.2	1	SNP	p	V57M	1	.	.	169	171	ATG	549	551	ATG	247;249;251	A;T;G	237;238;239	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
